Nuvation Bio Inc. financial data

Symbol
NUVB, NUVB-WT on NYSE
Industry
Pharmaceutical Preparations
Location
357 Tehama Street, Floor 3, San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Panacea Acquisition Corp (to 2/11/2021)
Latest financial report
Q1 2024 - Jun 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.19 K % -5.78%
Debt-to-equity 2.94 % -0.34%
Return On Equity -86.6 % -449%
Return On Assets -84.1 % -450%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 247 M shares +13%
Common Stock, Shares, Outstanding 219 M shares +0.13%
Entity Public Float 261 B USD -44.3%
Common Stock, Value, Issued 953 M USD +2.15%
Weighted Average Number of Shares Outstanding, Basic 219 K shares +0.14%
Weighted Average Number of Shares Outstanding, Diluted 219 K shares +0.14%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 65.3 M USD -23.9%
General and Administrative Expense 28.2 M USD -12.5%
Operating Income (Loss) -93.5 M USD +20.8%
Nonoperating Income (Expense) 24.6 M USD +83.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -68.9 M USD +34.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -527 M USD -404%
Earnings Per Share, Basic -0.32 USD/shares +33.3%
Earnings Per Share, Diluted -0.32 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 34.5 M USD +14.8%
Marketable Securities, Current 562 M USD -8.77%
Assets, Current 608 M USD -6.82%
Property, Plant and Equipment, Net 686 K USD -18.1%
Operating Lease, Right-of-Use Asset 3.17 M USD -9.97%
Other Assets, Noncurrent 1.08 M USD
Assets 613 M USD -6.69%
Accounts Payable, Current 2.44 M USD -17.3%
Accrued Liabilities, Current 11.3 M USD +35.2%
Liabilities, Current 15.8 M USD +25.6%
Accrued Income Taxes, Noncurrent 144 K USD +28.6%
Operating Lease, Liability, Noncurrent 1.51 M USD -44.7%
Liabilities 19.1 M USD +19.4%
Common Stocks, Including Additional Paid in Capital 117 M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.17 M USD +60.2%
Retained Earnings (Accumulated Deficit) -358 M USD -23.9%
Stockholders' Equity Attributable to Parent 594 M USD -7.34%
Liabilities and Equity 613 M USD -6.69%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.7 M USD +18.8%
Net Cash Provided by (Used in) Financing Activities 21 K USD -93%
Net Cash Provided by (Used in) Investing Activities 7.54 M USD
Common Stock, Shares Authorized 1.06 B shares 0%
Common Stock, Shares, Issued 219 M shares +0.13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.14 M USD +88.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 34.5 M USD +14.8%
Deferred Tax Assets, Valuation Allowance 100 M USD +18%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 101 M USD +17.7%
Operating Lease, Liability 3.53 M USD -11.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -67.1 M USD +33.8%
Lessee, Operating Lease, Liability, to be Paid 3.76 M USD -13.6%
Property, Plant and Equipment, Gross 1.38 M USD +2.29%
Operating Lease, Liability, Current 2.02 M USD +62.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.42 M USD -5.28%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.63 M USD +52.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +16.7%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 228 K USD -39.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 629 K USD -41.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.3 M USD +32%
Unrecognized Tax Benefits 5.63 M USD +11.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 81 K USD -87.2%
Share-based Payment Arrangement, Expense 19.7 M USD +12.3%